Compare Cassava Sciences Inc (FLNA) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Jones Lang LaSalle Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Jones Lang LaSalle Inc trades at $360.7 (market cap $16.72B). The key difference: Jones Lang LaSalle Inc is far larger — about 350.2× Cassava Sciences Inc's market cap, and Jones Lang LaSalle Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | JLL | |
|---|---|---|
Market Cap | $47.75M | $16.72B |
Sector | Health | Real Estate |
52-Week High | $4.64 | $373.24 |
52-Week Low | $0.87 | $280.16 |
Enterprise Value | -$34.93M | $19.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
JLL trades at $363.49, up 1.72% today, near its 52-week high. The stock exhibits bullish technical signals with a golden cross and strong momentum, supported by consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income margin improving to 3.64%. Analyst consensus is bullish with a $391.50 price target, and institutional holdings show confidence from firms like Bank of America.
Outlook remains positive driven by earnings growth and operational strength, but risks include economic sensitivity and competitive pressures. The stock offers upside to consensus targets, though valuation metrics like P/E of 17.43 require monitoring for sustainability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
